A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Cytokinetics
- Study ID
- NCT06081894
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Aficamten — DRUGOral Tablet
- Placebo — DRUGOral Tablet
Study Details
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Key Dates
- First listed
- Oct 13, 2023
- Start date
- Aug 31, 2023
- Status verified
- Sep 2026
- Primary completion
- Aug 31, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AficamtenParticipants in this arm will receive a single daily oral dose of 5 mg, 10 mg, 15 mg, or 20 mg of aficamten with dose levels guided by echocardiography assessments, for up to 72 weeks.
- Placebo Comparator: PlaceboParticipants in this arm will receive placebo, for up to 72 weeks.
Primary Outcome Measure
Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) [ Time Frame: Baseline to Week 36 ]
Locations (60)
Related coverage on Hipa.ai
- Aficamten Phase 3 Trial Lists Primary Completion for August 2026Aficamten · Aug 31, 2026 · ClinicalTrials.gov
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham· Birmingham, ALUC San Diego Health - Sulpizio Cardiovascular Center· La Jolla, CACedars-Sinai Medical Center (Smidt Heart Institute)· Los Angeles, CAKeck Medical Center of USC (Outpatient Clinic)· Los Angeles, CAUCLA Medical Center Cardiovascular Clinic· Los Angeles, CAUniversity of California San Francisco· San Francisco, CA